Clinical trials: SLE Nephritis
Refractory Systemic Lupus Erythematosus
Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)
This study will explore a new approach to treat patients with a medical condition known as systemic lupus erythematosus (SLE) who have been resistant to previous treatments using a new population of cells with capability to…
- Trial name
- NCT00698191
- Testing
- Allogeneic MSC (AlloMSC)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing Medical University
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
This was a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF…
- Trial name
- LUNAR (NCT00282347)
- Testing
- Rituximab, Mycophenolate mofetil, Methylprednisolone
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.
Immune Nephritis, Autoimmune Diseases
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis
- Conditions
- Immune Nephritis, Autoimmune Diseases, Lupus Nephritis
- Trial name
- NCT05085418
- Testing
- Assigned Interventions CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Lupus Nephritis
RING - Rituximab for Lupus Nephritis With Remission as a Goal
OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at least 6 months of standard of care (SOC).
- Trial name
- RING (NCT01673295)
- Testing
- RTX infusions, Standard of Care
- Where
- Belgium
- Volunteers
- 194 people
- Sponsor
- Frédéric A. Houssiau, MD, PhD
Lupus Nephritis
Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis
This observation study is planned to evaluate the safety and efficacy of the subjects who received CS20AT04 in the phase 1 clinical trial.
- Trial name
- NCT04522505
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Corestemchemon, Inc.
Lupus Nephritis
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in…
- Trial name
- NCT00377637
- Testing
- Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 370 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis, Mesenchymal Stem Cells
Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis
This study would further evaluate the safety and efficacy of human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis (LN).
- Trial name
- NCT04318600
- Testing
- human amniotic mesenchymal stem cell
- Volunteers
- 16 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
Nephritis, Lupus
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis
This a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment for the induction therapy of refractory lupus nephritis (LN).
- Trial name
- NCT01328834
- Testing
- Tacrolimus Sustained-release Capsules (ADVAGRAF)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).
- Trial name
- NCT06585514
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital
Lupus Nephritis
Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis
In this study, we aimed to evaluate the long term efficacy, remission, survival and safety of autologous hematopoietic stem cell transplantation in patients with refractory lupus nephritis.
- Trial name
- NCT03828071
- Testing
- Autologous hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Nanjing University School of Medicine
Immunologic Diseases, Autoimmune Diseases
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
- Conditions
- Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis
- Trial name
- NCT00035308
- Testing
- Abetimus sodium (LJP 394)
- Where
- 82 sites in United States, Austria and 8 more
- Volunteers
- 330 people
- Sponsor
- La Jolla Pharmaceutical Company
Lupus Nephritis (LN)
High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)
The goal of this observational study is to learn about the long-term renal and patient's survival of lupus nephritis (LN) patients in China.
- Trial name
- HOPE (NCT06682507)
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
SLE - Systemic Lupus Erythematosus
Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder that affects individuals globally, yet there is a significant lack of data regarding its prevalence and management, particularly in Asian populations like…
- Trial name
- PAN-SLE (NCT07902622)
- Testing
- no active ingredient
- Where
- Pakistan
- Volunteers
- 3,000 people
- Sponsor
- Foundation University Islamabad
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Lupus Nephritis
Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
Prospective, multi-center, randomized, controlled, trial to compare tacrolimus with mycophenolate mofetil (MMF) for induces complete remission in lupus nephritis patients. The study duration is one year.
- Trial name
- NCT01580865
- Testing
- Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
- Where
- Thailand
- Volunteers
- 84 people
- Sponsor
- Ramathibodi Hospital